Bipolar disorder (BD) is a major psychiatric condition that afflicts about 1% of people. Symptoms of BD include sudden onset of depressive mood with loss of interest which alternates with a manic state of hyperactivity. The suffering of the patients and societal cost of this disorder requires the use of continued therapeutic management. Current medications—although vital for patients with BD—are not perfect solutions, given their potential side-effects and treatment resistance. This necessitates the development of better therapeutics for BD, including precision medicine. A major hindrance to this process, however, lies in our limited understanding of the underlying biological mechanisms of BD, i.e., its pathogenesis and the genetic architecture of people with BD. Several studies have linked BD with hereditary mutations, but recent genomic studies are now focusing on somatic mosaic variants—new mutations occurring during developmental stages—as another possible mechanism behind psychiatric disorders like BD.
In a new study published in Molecular Psychiatry on May 30, 2023, a team of researchers led by Associate Professor Masaki Nishioka of Juntendo University, Japan, investigated the association between mosaic variants and the risk of BD. The research team included Dr. Tadafumi Kato, also from Juntendo University, and Dr. Atsushi Takata from RIKEN Center for Brain Science. "Most analyses exploring the genetic mechanisms of BD involve extracting information from mutations that are shared among all the cells of the patients. However, mosaic de novo mutations or somatic mutations, which arise during development, are not shared among all the cells. We know very little about how these mutations influence diseases like BD. Therefore, for our study, we hypothesized that deleterious mosaic de novo variants (mDNVs) in the genes associated with developmental disorders may have a role in BD’s pathology," explains Dr. Nishioka.
The team recruited 235 participants with BD and 39 control participants without psychiatric disorders. They collected blood or saliva samples from the participants and analyzed the DNA extracted from these samples using deep exome sequencing (DES) to detect mosaic variants that originated during early development. Participants with BD had mosaic variants enriched in genes that are responsible for causing developmental disorders (DD) and autism spectrum disorder (ASD). Moreover, the proteins encoded by the DD/ASD genes with the proteins of the mosaic variants were closely linked and had more protein-protein interactions than expected.
Surprisingly, the team also found significant heteroplasmic mutations (another class of mosaic variants) in mitochondrial tRNA genes of participants with BD. For reference, some tRNA mutations are known to be pathogenic for other diseases. In fact, two participants with mitochondrial tRNA mutations had recurrent m.3243 A > G variants, which are known to be major causal variants for mitochondrial diseases, MELAS, which is a serious neurodevelopmental disorder. This finding complements other studies that have found that patients with mitochondrial diseases often exhibit symptoms of bipolar disorder or schizophrenia.
Furthermore, both the sets of deleterious mosaic variants—mDNVs and mitochondrial tRNA variants—were either absent or rarely observed in the control participants. These results indicate that the molecular mechanisms underlying DD/ASD could also contribute to BD in a compromised way through mosaic mutations. Moreover, they suggest that mitochondrial tRNA variants could be associated with BD despite the patient showing no obvious symptoms of mitochondrial diseases.
With this study, the researchers demonstrate that mosaic mutations, particularly those in neurodevelopmental disorder genes and mitochondrial tRNA genes, may be involved in the pathophysiology of BD. Dr. Nishioka is encouraged by what their study's findings mean for scientists pursuing the research of molecular pathologies in neuropsychiatric diseases. He concludes, "Our research sheds new light on the genetic architecture of BD and provides more insights into the pathological contribution of mosaic variants in human diseases. This could potentially pave the way and expedite new research for the development of more effective, precision medications for treating BD and other psychiatric disorders.”
Reference
Authors
Title of original paper
Journal
Masaki Nishioka 1,2,3,4, Jun Takayama5,6,7, Naomi Sakai1,3, An-a Kazuno3,4, Mizuho Ishiwata1,3, Junko Ueda3,4, Takashi Hayama8, Kumiko Fujii9, Toshiyuki Someya10, Shinichi Kuriyama11,12, Gen Tamiya5,6,7, Atsushi Takata 3,4,13 and Tadafumi Kato1,2,3
Deep exome sequencing identifies enrichment of deleterious mosaic variants in neurodevelopmental disorder genes and mitochondrial tRNA regions in bipolar disorder
Molecular Psychiatry
DOI
Affiliations
10.1038/s41380-023-02096-x
1Department of Psychiatry and Behavioral Science, Juntendo University Graduate School of Medicine, Japan.
2Department of Molecular Pathology of Mood Disorders, Juntendo University Graduate School of Medicine, Japan.
3Laboratory for Molecular Dynamics of Mental Disorders, RIKEN Center for Brain Science, Japan.
4Laboratory for Molecular Pathology of Psychiatric Disorders, RIKEN Center for Brain Science, Japan.
5Department of AI and Innovative Medicine, Tohoku University School of Medicine, Japan.
6Department of Integrative Genomics, Tohoku Medical Megabank Organization, Japan.
7Statistical Genetics Team, RIKEN Center for Advanced Intelligence Project, Japan.
8Yokohama Mental Clinic Totsuka, Japan.
9Department of Psychiatry, Shiga University of Medical Science, Japan.
10Department of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences, Japan.
11Department of Preventive Medicine and Epidemiology, Tohoku Medical Megabank Organization, Tohoku University, Japan.
12Department of Molecular Epidemiology, Tohoku University School of Medicine, Japan.
13Research Institute for Diseases of Old Age, Juntendo University Graduate School of Medicine, Japan.
END
